Prostate Cancer - Results from #260

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer. September 17, 2024

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study September 16, 2024

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. September 16, 2024

Proteomic landscape profiling of primary prostate cancer reveals a 16-protein panel for prognosis prediction. September 16, 2024

'Just because I have prostate cancer doesn't mean that I can't do things' - men's experiences of the acceptability of an exercise intervention for prostate cancer during treatment. September 16, 2024

Polyploid cancer cells reveal signatures of chemotherapy resistance. September 16, 2024

Fatigue Management in Advanced Prostate Cancer: Real-World Insights From Qualitative Interviews With Patients. September 16, 2024

Comparative Performance of 68Ga-PSMA-11 PET/CT and Conventional Imaging in the Primary Staging of High-Risk Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy. September 16, 2024

Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer. September 16, 2024

Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma. September 16, 2024

Targeted Prostate Biopsy: How, When, and Why? A Systematic Review. September 16, 2024

Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment. September 16, 2024

Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308. September 14, 2024

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells. September 14, 2024

Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer. September 14, 2024

Association of Baseline Magnetic Resonance Imaging Prostate Imaging Reporting and Data System Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC) September 13, 2024

SECuRE Trial Advances: No Dose Limiting Toxicities and Strong Preliminary Efficacy Data in First Multi-Dose Cohort September 13, 2024

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race. September 13, 2024

Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics. September 13, 2024

Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance. September 13, 2024

Page 14 of 1436